METTL3 antibody [N2C2], Internal
GTX105037
ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
Product group Antibodies
TargetMETTL3
Overview
- SupplierGeneTex
- Product NameMETTL3 antibody [N2C2], Internal
- Delivery Days Customer9
- Application Supplier NoteWB: 1:5000-1:20000. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.
- ApplicationsWestern Blot, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin
- CertificationResearch Use Only
- ClonalityPolyclonal
- Concentration0.54 mg/ml
- ConjugateUnconjugated
- Gene ID56339
- Target nameMETTL3
- Target descriptionmethyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit
- Target synonymsIME4, M6A, MT-A70, Spo8, hMETTL3, N(6)-adenosine-methyltransferase catalytic subunit METTL3, N(6)-adenosine-methyltransferase 70 kDa subunit, N6-adenosine-methyltransferase 70 kDa subunit, N6-adenosine-methyltransferase catalytic subunit, adoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase, mRNA (2'-O-methyladenosine-N(6)-)-methyltransferase, mRNA m(6)A methyltransferase, methyltransferase like 3, methyltransferase-like protein 3
- HostRabbit
- IsotypeIgG
- Protein IDQ86U44
- Protein NameN(6)-adenosine-methyltransferase catalytic subunit METTL3
- Scientific DescriptionThis gene encodes the 70 kDa subunit of MT-A which is part of N6-adenosine-methyltransferase. This enzyme is involved in the posttranscriptional methylation of internal adenosine residues in eukaryotic mRNAs, forming N6-methyladenosine. [provided by RefSeq]
- Storage Instruction-20°C or -80°C,2°C to 8°C
- UNSPSC12352203
References
- Chang X, Lv YF, He J, et al. Gene Expression Profile and Prognostic Value of m6A RNA Methylation Regulators in Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021,8:85-101. doi: 10.2147/JHC.S296438Read this paper
- Liang S, Guan H, Lin X, et al. METTL3 serves an oncogenic role in human ovarian cancer cells partially via the AKT signaling pathway. Oncol Lett. 2020,19(4):3197-3204. doi: 10.3892/ol.2020.11425Read this paper





